REGENERON PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 5, 2024
REGN$919.96+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
As disclosed in the table below, during the three months ended December 31, 2023, certain of our directors and/or executive officers adopted plans for trading arrangements intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act.
| Name | Position | Date of Plan Adoption | Scheduled End Date of Trading Arrangement(a) | Total Number of Securities to Be Sold Under the Plan |
|---|---|---|---|---|
| Robert E. Landry | Executive Vice President, Finance and Chief Financial Officer | 11/9/2023 | 5/6/2024 | 14,337 |
| (a) The trading arrangement may expire on an earlier date if and when all transactions under the arrangement are completed. | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.